Sunshine Biopharma Warrant Stock Current Valuation
| SBFMW Stock | USD 0.21 0.01 4.55% |
Valuation analysis of Sunshine Biopharma helps investors to measure Sunshine Biopharma's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value Over EBITDA is likely to climb to 2.48 in 2024. Enterprise Value Multiple is likely to climb to 2.48 in 2024.
Overvalued
Today
Please note that Sunshine Biopharma's price fluctuation is out of control at this time. Calculation of the real value of Sunshine Biopharma is based on 3 months time horizon. Increasing Sunshine Biopharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Sunshine stock is determined by what a typical buyer is willing to pay for full or partial control of Sunshine Biopharma Warrant. Since Sunshine Biopharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Sunshine Stock. However, Sunshine Biopharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.21 | Real 0.17 | Hype 0.28 | Naive 0.19 |
The intrinsic value of Sunshine Biopharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Sunshine Biopharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Sunshine Biopharma Warrant helps investors to forecast how Sunshine stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Sunshine Biopharma more accurately as focusing exclusively on Sunshine Biopharma's fundamentals will not take into account other important factors: Sunshine Biopharma Warrant Company Current Valuation Analysis
Sunshine Biopharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Sunshine Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Sunshine Biopharma is extremely important. It helps to project a fair market value of Sunshine Stock properly, considering its historical fundamentals such as Current Valuation. Since Sunshine Biopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Sunshine Biopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Sunshine Biopharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Sunshine Biopharma Warrant has a Current Valuation of 0.0. This is 100.0% lower than that of the Biotechnology sector and about the same as Health Care (which currently averages 0.0) industry. The current valuation for all United States stocks is 100.0% higher than that of the company.
Sunshine Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sunshine Biopharma's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sunshine Biopharma could also be used in its relative valuation, which is a method of valuing Sunshine Biopharma by comparing valuation metrics of similar companies.Sunshine Biopharma is currently under evaluation in current valuation category among its peers.
Sunshine Fundamentals
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | (0.13) % | ||||
| Operating Margin | (0.13) % | ||||
| Number Of Shares Shorted | 3.96 K | ||||
| Revenue | 24.09 M | ||||
| Gross Profit | 110.6 K | ||||
| EBITDA | (3.82 M) | ||||
| Net Income | (4.51 M) | ||||
| Cash And Equivalents | 40.56 M | ||||
| Cash Per Share | 1.80 X | ||||
| Total Debt | 657.71 K | ||||
| Debt To Equity | 8.98 % | ||||
| Current Ratio | 85.09 X | ||||
| Book Value Per Share | 12.52 X | ||||
| Cash Flow From Operations | (8.78 M) | ||||
| Earnings Per Share | (2.21) X | ||||
| Number Of Employees | 44 | ||||
| Beta | -1.04 | ||||
| Total Asset | 27.35 M | ||||
| Retained Earnings | (63.91 M) | ||||
| Working Capital | 19.34 M | ||||
| Net Asset | 27.35 M |
About Sunshine Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sunshine Biopharma Warrant's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sunshine Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sunshine Biopharma Warrant based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Sunshine Stock Analysis
When running Sunshine Biopharma's price analysis, check to measure Sunshine Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sunshine Biopharma is operating at the current time. Most of Sunshine Biopharma's value examination focuses on studying past and present price action to predict the probability of Sunshine Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sunshine Biopharma's price. Additionally, you may evaluate how the addition of Sunshine Biopharma to your portfolios can decrease your overall portfolio volatility.